Want to see CV full AI Analyst Report?
Top Page
CapsoVision, Inc.
(NASDAQ:CV)
Select Model
Select Model
Rating:43Neutral
Price Target:
$5.50
▼(-58.43% Downside)
Action:Reiterated
Date:07/08/26
The score is primarily constrained by weak financial performance: very large net losses and sustained negative operating/free cash flow outweigh strong revenue growth and stable gross margins. Technicals also lean negative with the stock trading below key moving averages. Valuation provides limited support due to losses and no dividend, while recent corporate governance/board updates are a modest positive.
Positive Factors
Revenue & Gross Margin
Sustained double‑digit top‑line growth alongside stable mid‑50s gross margins indicates durable product demand and unit economics in capsule endoscopy. This combination supports scalable revenue expansion and the potential for operating leverage as fixed costs are absorbed over time.
Negative Factors
Cash Burn & Weak Cash Flow
Consistently large negative operating and free cash flows over multiple years create a structural dependence on external financing. Persistent cash burn constrains strategic flexibility, raises dilution risk, and makes long‑term product investment contingent on securing durable funding sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Gross Margin
Sustained double‑digit top‑line growth alongside stable mid‑50s gross margins indicates durable product demand and unit economics in capsule endoscopy. This combination supports scalable revenue expansion and the potential for operating leverage as fixed costs are absorbed over time.
Read all positive factors
CapsoVision, Inc. (CV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$299.28M
Dividend YieldN/A
Average Volume (3M)45.47K
Price to Earnings (P/E)―
Beta (1Y)-1.75
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees99
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-1.05
Shares Outstanding49,963,585
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)197.96
Price to Sales (P/S)193.67
P/FCF Ratio-114.36
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue22.68
Enterprise Value/Gross Profit43.90
Enterprise Value/Ebitda-11.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$15.80M
CapsoVision, Inc. Business Overview & Revenue Model
Company Description
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization o...
How the Company Makes Money
null...
CapsoVision, Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 13.56M | 13.55M | 11.76M | 9.75M |
| Gross Profit | 7.01M | 7.17M | 6.38M | 5.49M |
| EBITDA | -26.65M | -24.95M | -19.40M | -10.96M |
| Net Income | -26.97M | -25.32M | -19.90M | -11.30M |
Balance Sheet | ||||
| Total Assets | 25.95M | 18.16M | 16.80M | 21.53M |
| Cash, Cash Equivalents and Short-Term Investments | 17.93M | 10.11M | 9.32M | 14.56M |
| Total Debt | 788.00K | 887.00K | 1.24M | 1.51M |
| Total Liabilities | 5.72M | 4.90M | 146.31M | 131.37M |
| Stockholders Equity | 20.22M | 13.26M | -129.51M | -109.84M |
Cash Flow | ||||
| Free Cash Flow | -24.04M | -22.95M | -20.24M | -11.56M |
| Operating Cash Flow | -23.94M | -22.86M | -20.09M | -10.80M |
| Investing Cash Flow | -98.00K | -90.00K | -153.00K | -754.00K |
| Financing Cash Flow | 37.52M | 23.60M | 15.07M | 20.53M |
CapsoVision, Inc. Risk Analysis
CapsoVision, Inc. disclosed 69 risk factors in its most recent earnings report. CapsoVision, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CapsoVision, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $37.93B | 26.86 | 20.84% | 0.72% | 9.11% | 22.77% | |
62 Neutral | $4.22B | 62.43 | 2.18% | ― | 12.15% | ― | |
58 Neutral | $528.47M | -17.03 | -17.65% | ― | 10.73% | 25.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $299.28M | -5.92 | 126.84% | ― | ― | ― |
* Healthcare Sector Average
CV
CapsoVision, Inc.
6.22
1.63
35.51%
A
Agilent
134.04
22.00
19.64%
ANGO
AngioDynamics
12.78
4.13
47.69%
NVST
Envista Holdings
26.22
6.41
32.36%
PFSA
Profusa
2.21
-2,679.04
-99.92%
CapsoVision, Inc. Corporate Events
Business Operations and StrategyExecutive/Board Changes
CapsoVision adds Shields to board, refines clinical focus
Positive
Jul 2, 2026
On July 1, 2026, CapsoVision appointed veteran gastroenterologist and longtime clinical advisor Dr. David S. Shields to its Board of Directors and Compensation Committee, filling the vacancy created by the same-day resignation of director Dr. Joan...
Executive/Board ChangesShareholder Meetings
CapsoVision Stockholders Reelect Directors, Ratify 2026 Auditor
Positive
Jun 12, 2026
CapsoVision Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where shareholders voted on director elections and auditor ratification. The meeting outcomes confirm continuity in board leadership and financial oversight, signaling...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.